Adaptive Biotechnologies Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	55.03	47.92	65.06	90.03	139.07	123.44
Short-Term Investments	157.74	174.37	281.34	408.17	214	564.83
Cash & Short-Term Investments	212.77	222.29	346.4	498.2	353.06	688.27
Cash Growth	-12.56%	-35.83%	-30.47%	41.11%	-48.70%	19.31%
Accounts Receivable	44.82	41.73	37.97	40.06	17.41	10.05
Other Receivables	1.5	1.3	1	0.8	1.4	2.5
Receivables	46.32	43.03	38.97	40.86	18.81	12.55
Inventory	9.93	8.44	14.45	14.45	19.26	14.06
Prepaid Expenses	12.41	9.99	10.37	8.64	11.62	12.04
Total Current Assets	281.44	283.75	410.19	562.15	402.75	726.91
Property, Plant & Equipment	79.49	94.38	120.32	164.21	172.94	139.04
Long-Term Investments	4.04	33.66	-	-	217.15	118.53
Goodwill	118.97	118.97	118.97	118.97	118.97	118.97
Other Intangible Assets	2.16	3.43	5.13	6.83	8.53	10.23
Other Long-Term Assets	4.53	5.18	6.52	4.46	3.01	2.74
Total Assets	490.61	539.38	661.13	856.62	923.34	1,116
Accounts Payable	10.27	7.27	7.72	8.08	3.31	3.24
Accrued Expenses	19.89	20.67	20.39	24.1	22.2	18.92
Current Portion of Long-Term Debt	2.43	0.87	-	-	-	-
Current Portion of Leases	9.44	10.24	9.38	9.23	5.06	3.53
Current Income Taxes Payable	-	0.18	0.06	0.19	0.39	0.37
Current Unearned Revenue	41.34	55.69	48.63	64.12	80.46	73.32
Other Current Liabilities	-	3.15	1.84	4.07	2.39	5.82
Total Current Liabilities	83.36	98.05	88.02	109.79	113.81	105.2
Long-Term Debt	129.41	132.41	130.66	125.36	-	-
Long-Term Leases	72.36	79.15	89.39	98.77	106.69	104.33
Long-Term Unearned Revenue	1.21	27.26	44.79	58.6	98.75	163.62
Other Long-Term Liabilities	0.02	0.02	-	-	-	-
Total Liabilities	286.36	336.89	352.86	392.52	319.24	373.15
Common Stock	0.02	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	1,554	1,506	1,453	1,387	1,324	1,254
Retained Earnings	-1,350	-1,304	-1,144	-919.08	-718.89	-511.61
Comprehensive Income & Other	0.21	0.17	0.22	-4.12	-1.14	0.89
Total Common Equity	204.44	202.71	308.4	464.17	603.99	743.27
Minority Interest	-0.18	-0.22	-0.12	-0.07	0.11	-
Shareholders' Equity	204.25	202.49	308.28	464.1	604.1	743.27
Total Liabilities & Equity	490.61	539.38	661.13	856.62	923.34	1,116
Total Debt	213.64	222.67	229.43	233.36	111.74	107.86
Net Cash (Debt)	3.17	33.29	116.97	264.83	458.47	698.93
Net Cash Growth	-92.58%	-71.54%	-55.83%	-42.23%	-34.41%	8.24%
Net Cash Per Share	0.02	0.23	0.81	1.86	3.27	5.33
Filing Date Shares Outstanding	152.67	148.58	145.09	143.23	141.58	139.22
Total Common Shares Outstanding	152.58	147.77	145.08	143.11	141.39	137.65
Working Capital	198.07	185.7	322.17	452.36	288.94	621.72
Book Value Per Share	1.34	1.37	2.13	3.24	4.27	5.40
Tangible Book Value	83.31	80.31	184.3	338.37	476.49	614.07
Tangible Book Value Per Share	0.55	0.54	1.27	2.36	3.37	4.46
Machinery	-	59.33	61.36	56.7	48.88	34.08
Construction In Progress	-	2.57	3.41	7.63	5.66	7.19
Leasehold Improvements	-	73.28	74.73	72.4	65.96	21.95

Source: S&P Global Market Intelligence. Standard template. Financial Sources.